Emyria Ltd (ASX:EMD) and its partner, the University of Western Australia (UWA), have shipped the fourth batch of unique MDMA analogues, sending 14 new compounds for safety screening with Eurofins and bringing its library to more than 140 individual analogues.
Emyria and the UWA have been actively generating and screening a drug-discovery pipeline of novel MDMA analogues to identify new chemical compounds and drug candidates with the potential to address unmet needs in mental health and neurological disorders.
Select compounds to begin clinical screening
Five more compounds have also been sent to PsychoGenics in the US to begin advanced preclinical screening, leveraging the US company’s SmartCube™ platform to accelerate development and commercialisation.
Read: Emyria begins US-based preclinical program with leading neuroscience drug discovery research organisation
An Australian Clinical Research Organisation (CRO) will also screen a set of priority compounds for additional metabolic studies in mice, rat and human liver cells, to aid in determining the metabolic half-life of these compounds.